Latest Regulatory Approvals News

Sayona Mining Limited and Piedmont Lithium Inc. have agreed to merge, creating a leading North American lithium producer with complementary assets and a balanced ownership structure. The merger, subject to regulatory and shareholder approvals, aims to unlock significant synergies and strengthen the combined company’s financial position.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.

New World Resources has secured a crucial environmental permit for its Antler Copper Project in Arizona, accelerating its path toward construction. This milestone reflects strong state support and positions the company to begin building later in 2025.

Enova Mining advances its CODA Central project in Brazil with six auger holes completed, targeting promising titanium and rare earth mineralisation. Assay results are anticipated by late July, alongside ongoing metallurgical testing to unlock processing pathways.

PointsBet shareholders have voted in favour of the proposed $1.20 per share acquisition by MIXI, Inc, marking a significant premium and clearing a key hurdle ahead of court approval.

Carnaby Resources reports robust drill results from its Trekelano Project, revealing a broadening copper-gold mineralised zone with high-grade intervals that suggest significant deposit growth potential.

Brightstar Resources has signed a pivotal Memorandum of Understanding with Paddington Gold, setting the stage for open pit mining at the Lady Shenton deposit starting early 2026. This agreement promises to significantly boost production and de-risk the Menzies Gold Project.

Xero Limited has announced a binding agreement to acquire Melio Limited for US$2.5 billion, backed by a fully underwritten A$1.85 billion equity raise. This strategic move aims to accelerate Xero’s US growth and more than double its FY25 revenue by FY28.

Xero Limited has agreed to acquire Melio Limited, a leading US SMB bill pay platform, for US$2.5 billion, marking a significant leap in its US growth strategy. The deal is backed by a substantial A$1.85 billion equity raise and aims to accelerate revenue and market presence by FY28.

Cyprium Metals has obtained crucial environmental and operational approvals to advance the phased redevelopment of its Nifty Copper Complex, setting the stage for a near-term production restart.

Radiopharm Theranostics has inked a clinical supply agreement with Cyclotek to support its Phase 1 trial of RAD 402, a novel radiotherapeutic targeting prostate cancer, set to commence in Australia in late 2025.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.